Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Expert View: Wearable Technology And The FDA Adoption Curve

This article was originally published in Scrip

Executive Summary

The US FDA recently announced that it will carefully consider the value of mobile technology in clinical research. By and large, the process of testing and approving new drugs and therapies has remained unchanged for the past 50 years. Today, data collected in everyday devices like smartphones and wearable fitness trackers could make clinical trials safer for patients and provide meaningful data to the FDA, write Barbara Elashoff and Glen de Vries of Medidata Solutions.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts